Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

44.0%

11 terminated/withdrawn out of 25 trials

Success Rate

56.0%

-30.5% vs industry average

Late-Stage Pipeline

8%

2 trials in Phase 3/4

Results Transparency

79%

11 of 14 completed trials have results

Key Signals

11 with results11 terminated

Enrollment Performance

Analytics

Phase 2
15(62.5%)
Phase 1
4(16.7%)
N/A
3(12.5%)
Phase 3
2(8.3%)
24Total
Phase 2(15)
Phase 1(4)
N/A(3)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials
NCT01919853Not ApplicableCompleted

Treatment for Persistently Fatigued Cancer Survivors: A Randomized Controlled Trial With Biomarker Response

Role: collaborator

NCT02101385Phase 2Completed

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Role: collaborator

NCT00379912Phase 2Terminated

Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

Role: collaborator

NCT00216203Phase 1Completed

Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer

Role: collaborator

NCT00216099Phase 2Completed

Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer

Role: collaborator

NCT02367508Not ApplicableCompleted

Mindfully Optimizing Delivery of End-of-Life Care

Role: collaborator

NCT00417248Phase 1Terminated

Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer

Role: collaborator

NCT00216086Phase 2Terminated

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer

Role: collaborator

NCT00216060Phase 3Terminated

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

Role: collaborator

NCT00319735Phase 2Completed

Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas

Role: collaborator

NCT00216125Phase 3Completed

Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer

Role: collaborator

NCT00234494Phase 2Completed

Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer

Role: collaborator

NCT00216112Phase 2Completed

Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer

Role: collaborator

NCT00367601Phase 2Completed

Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

Role: collaborator

NCT00216021Phase 2Completed

Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer

Role: collaborator

NCT00216047Phase 1Terminated

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

Role: collaborator

NCT00235235Terminated

A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Role: collaborator

NCT00216073Phase 2Terminated

Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer

Role: collaborator

NCT00216164Phase 2Terminated

Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Role: collaborator

NCT00216138Phase 2Terminated

Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck

Role: collaborator